On this page

Begin with the intended goal

Embolization uses a catheter-based approach to deliver material that blocks selected abnormal vascular connections. Its meaning depends on the plan: it may support surgery, address a specific feature, aim for complete obliteration in selected lesions or palliate symptoms when complete treatment is not feasible. “Embolized” does not by itself mean the AVM is gone or that no further treatment is planned.1

Angiographic anatomy, rupture status, lesion location and the treating team's expertise affect the approach. Embolization should be considered within a comprehensive multidisciplinary plan. Explaining the intended endpoint before the procedure makes the later result easier to interpret.12

Four contexts to distinguish

Adjunctive embolization may prepare an AVM for surgery, for example by addressing vessels that complicate resection. Its risks need to be justified by the proposed benefit for the overall plan. Use before radiosurgery has different planning issues, and SNIS describes that role as not well established. It is not a routine requirement for everyone receiving either treatment.1

Targeted embolization addresses a particular feature, such as an aneurysm judged to be the source of hemorrhage in a ruptured AVM. It may leave a residual nidus intentionally. Whether the feature has been treated successfully is a different endpoint from complete AVM obliteration, and the remaining lesion still needs a plan.1

Curative-intent embolization seeks complete elimination of the shunt in a selected lesion. Intent does not establish the outcome. The SNIS report identifies uncertainty about this approach compared with other modalities and about durability and recurrence; promising selected series are not proof of universal suitability.1

Palliative embolization may be considered for certain symptomatic lesions when curative therapy is not possible. The aim may be symptom relief or limiting deterioration rather than complete closure. Supporting data are limited, so the proposed clinical benefit and how it will be measured need explicit discussion.1

What can go wrong?

Potential complications include hemorrhage, ischemic injury and new neurological deficits. Risks can arise from catheter work, unintended vessel occlusion or changes in flow during treatment. A staged or adjunctive procedure has its own risks even when another procedure is expected to finish the plan. The total treatment course matters, not just whether one session technically reached its target.1

Partial treatment is not automatically useless, and it is not inevitably harmful in every context. It also should not be described as complete protection from future bleeding. The intended target, remaining anatomy and evidence for that strategy determine the discussion. Distinguish a planned targeted procedure from an incomplete attempt at full obliteration.1

Interpreting evidence and follow-up

A device-specific or single-center result depends on the selected population and treatment intent. ARUBA compared mixed intervention with medical management in adults with unruptured AVMs; it was not a randomized comparison between embolic agents or embolization goals.3

Ask which vessels or features will be treated, whether complete obliteration is expected, whether other stages remain and how success and complications will be checked. Angiographic closure, maintained function and symptom response are distinct outcomes. Follow-up after apparent obliteration can detect residual or recurrent shunting; its modality and timing belong with the treating team.1

References

  1. De Leacy R et al. J NeuroIntervent Surg. 2022;14:1118–1124. doi:10.1136/neurintsurg-2021-018632. Source ↩
  2. Derdeyn CP et al. Stroke. 2017;48:e200–e224. doi:10.1161/STR.0000000000000134. Official Top Things to Know summary. Source ↩
  3. Mohr JP et al. Lancet Neurol. 2020;19:573–581. doi:10.1016/S1474-4422(20)30181-2. PubMed ↩